Gallego-Colon, Enrique <br/><br/>
Exenatide modulates metalloproteinase expression in human cardiac smooth muscle cells via the inhibition of Akt signaling pathway.  [electronic resource] 

 -  Pharmacological reports : PR  Feb 2018 
 - 178-183 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>2299-5684 
<br/><br/><label>Standard No.: </label>10.1016/j.pharep.2017.10.003  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Cells, Cultured<br/>Cellular Microenvironment<br/>Collagenases--genetics<br/>Coronary Vessels--drug effects<br/>Dose-Response Relationship, Drug<br/>Exenatide<br/>Glucagon-Like Peptide-1 Receptor--metabolism<br/>Humans<br/>Incretins--pharmacology<br/>Matrix Metalloproteinase 1--genetics<br/>Matrix Metalloproteinase 2--genetics<br/>Matrix Metalloproteinase 9--genetics<br/>Muscle, Smooth, Vascular--drug effects<br/>Myocytes, Smooth Muscle--drug effects<br/>Peptides--pharmacology<br/>Phosphorylation<br/>Proto-Oncogene Proteins c-akt--metabolism<br/>Signal Transduction--drug effects<br/>Tissue Inhibitor of Metalloproteinase-1--genetics<br/>Tissue Inhibitor of Metalloproteinase-2--genetics<br/>Tumor Necrosis Factor-alpha--pharmacology<br/>Venoms--pharmacology<br/>Glucagon-Like Peptide-1 Receptor Agonists